End-of-day quote
Shanghai S.E.
06:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
36.48
CNY
|
-0.38%
|
|
-5.74%
|
-21.48%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,423
|
12,508
|
16,740
|
25,873
|
20,315
|
-
|
-
|
Enterprise Value (EV)
1 |
7,423
|
12,508
|
16,740
|
25,873
|
20,315
|
20,315
|
20,315
|
P/E ratio
|
111
x
|
-23.9
x
|
47.7
x
|
31.4
x
|
18.8
x
|
14.3
x
|
12.6
x
|
Yield
|
-
|
-
|
-
|
0.65%
|
1.59%
|
1.74%
|
1.97%
|
Capitalization / Revenue
|
-
|
1.03
x
|
1.19
x
|
1.66
x
|
1.14
x
|
0.94
x
|
0.91
x
|
EV / Revenue
|
-
|
1.03
x
|
1.19
x
|
1.66
x
|
1.14
x
|
0.94
x
|
0.91
x
|
EV / EBITDA
|
-
|
-63
x
|
19.2
x
|
18.7
x
|
11.5
x
|
8.94
x
|
8.63
x
|
EV / FCF
|
-
|
-
|
-
|
-3,066
x
|
15.3
x
|
13.2
x
|
13.9
x
|
FCF Yield
|
-
|
-
|
-
|
-0.03%
|
6.53%
|
7.55%
|
7.2%
|
Price to Book
|
-
|
4.59
x
|
5.46
x
|
7.14
x
|
4.43
x
|
3.35
x
|
2.84
x
|
Nbr of stocks (in thousands)
|
556,891
|
556,891
|
556,891
|
556,891
|
556,891
|
-
|
-
|
Reference price
2 |
13.33
|
22.46
|
30.06
|
46.46
|
36.48
|
36.48
|
36.48
|
Announcement Date
|
4/23/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
12,149
|
14,051
|
15,623
|
17,823
|
21,675
|
22,323
|
EBITDA
1 |
-
|
-198.5
|
871.5
|
1,382
|
1,767
|
2,273
|
2,355
|
EBIT
1 |
-
|
-497.4
|
430
|
1,023
|
1,343
|
1,819
|
2,015
|
Operating Margin
|
-
|
-4.09%
|
3.06%
|
6.55%
|
7.53%
|
8.39%
|
9.03%
|
Earnings before Tax (EBT)
1 |
-
|
-494.1
|
442.8
|
1,027
|
1,349
|
1,827
|
2,020
|
Net income
1 |
66.07
|
-523.2
|
349.7
|
822.1
|
1,080
|
1,420
|
1,609
|
Net margin
|
-
|
-4.31%
|
2.49%
|
5.26%
|
6.06%
|
6.55%
|
7.21%
|
EPS
2 |
0.1200
|
-0.9395
|
0.6300
|
1.480
|
1.940
|
2.550
|
2.888
|
Free Cash Flow
1 |
-
|
-
|
-
|
-8.439
|
1,326
|
1,534
|
1,463
|
FCF margin
|
-
|
-
|
-
|
-0.05%
|
7.44%
|
7.08%
|
6.55%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
75.06%
|
67.5%
|
62.13%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
122.79%
|
108.01%
|
90.93%
|
Dividend per Share
2 |
-
|
-
|
-
|
0.3000
|
0.5800
|
0.6350
|
0.7200
|
Announcement Date
|
4/23/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-8.44
|
1,326
|
1,534
|
1,463
|
ROE (net income / shareholders' equity)
|
-
|
-17.5%
|
12.1%
|
23.8%
|
23.7%
|
23.6%
|
22.5%
|
ROA (Net income/ Total Assets)
|
-
|
-3.78%
|
2.51%
|
-
|
6.73%
|
7.08%
|
7.53%
|
Assets
1 |
-
|
13,828
|
13,938
|
-
|
16,062
|
20,075
|
21,361
|
Book Value Per Share
2 |
-
|
4.900
|
5.500
|
6.500
|
8.230
|
10.90
|
12.90
|
Cash Flow per Share
2 |
-
|
1.000
|
3.230
|
1.210
|
2.490
|
3.470
|
3.890
|
Capex
1 |
-
|
220
|
432
|
680
|
648
|
1,762
|
588
|
Capex / Sales
|
-
|
1.81%
|
3.07%
|
4.35%
|
3.63%
|
8.13%
|
2.63%
|
Announcement Date
|
4/23/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
36.48
CNY Average target price
52.83
CNY Spread / Average Target +44.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.48% | 2.81B | | +38.51% | 727B | | +33.05% | 599B | | -6.23% | 354B | | +18.78% | 328B | | +1.35% | 277B | | +16.00% | 243B | | +8.09% | 205B | | -5.77% | 203B | | +6.19% | 164B |
Other Pharmaceuticals
|